🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Consumer Discretionary Sector SEC Filings — August 12, 2026

The latest batch of 9 filings for the S&P 500 Consumer Discretionary stream reveals a sector dominated by passive institutional positioning, with Capital Group entities (Capital World Investors, Capital Research Global Investors) making notable disclosures in Chipotle, Starbucks, Nike, and Carvana. The most actionable signal comes from Aptiv PLC, where a director made a significant open-market purchase of $552K at ~$50.21-$50.29, a strong vote of confidence given the stock's recent pullback. Home Depot's 8-K introduces a temporary leadership vacuum as CEO Ted Decker takes medical leave, creating near-term uncertainty for the 2,361-store giant. Period-over-period comparisons are limited in these filings, but the insider buying at Aptiv and the stable, passive stakes across the consumer giants suggest a sector that is attractively valued but lacking immediate catalysts. The absence of forward-looking guidance or capital allocation changes in most filings points to a wait-and-see posture from management teams. The key portfolio-level pattern is the concentration of large passive holders (Capital Group) across multiple consumer discretionary names, indicating a coordinated or thematic allocation to the sector.

2 high priority 7 medium 9 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — August 12, 2026

Today's healthcare filings are dominated by insider trading activity, revealing a clear divergence in management sentiment. Pfizer CEO Albert Bourla made a notable $1M open-market purchase, signaling strong conviction at a depressed valuation, while multiple executives at Regeneron, Merck, and Becton Dickinson executed significant sales, often via 10b5-1 plans. The sector also saw a passive institutional stake disclosure in Moderna by Capital World Investors, indicating steady interest despite the company's challenges. The overall pattern suggests a bifurcated market: large-cap pharma with strong pipelines and cash flows are attracting insider buying, while high-growth or device companies are seeing profit-taking. No period-over-period financial trends or forward-looking guidance were available in these filings, limiting the ability to assess operational momentum. The most actionable signal is the bullish insider activity at Pfizer, which contrasts with the broader selling trend.

8 high priority 1 medium 9 total filings
· daily

US Earnings Financial Results SEC Filings — August 12, 2026

The 50 filings for the period ending mid-2026 reveal a market characterized by a stark divergence between top-line growth and bottom-line profitability. While several companies, particularly in infrastructure (Cardinal, CoreWeave) and consumer (CAVA, Nucor), posted robust revenue growth, a significant number of firms are experiencing margin compression and widening net losses due to rising costs, heavy investment, and non-cash charges. A notable theme is the prevalence of 'mixed' sentiment, with 27 out of 50 filings showing both positive and negative signals, often driven by strong revenue growth offset by surging operating expenses and interest costs. Insider trading activity was notably absent from the enriched data, limiting one key signal source. Capital allocation trends show a bifurcation: mature companies like Nucor are returning capital via buybacks and dividends, while growth and pre-revenue firms are aggressively raising capital through equity and debt offerings to fund operations and expansion. The healthcare and biotech sector is a major focal point, with several companies (Liquidia, Protalix) achieving dramatic turnarounds, while others (Sutro, Arbutus) face significant revenue volatility. The data suggests investors should prioritize companies demonstrating operating leverage and cash flow discipline over those solely focused on top-line expansion.

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — August 12, 2026

This digest of four pre-analyzed proxy filings reveals a stark divergence in corporate governance and financial health across the US equity market. The most critical development is at **Beauty Health Co (SKIN)**, where a severe liquidity crisis is unfolding: the company faces a potential $353.2M note repurchase obligation if a reverse stock split fails, far exceeding its $206.1M cash position, creating a high-probability distress scenario. In contrast, **Fossil Group, Inc.** is pursuing a more standard governance refresh, reducing its board size and seeking shareholder approval for a compensation plan amendment, indicating a focus on long-term incentive alignment. **Thirdline Real Estate Income Fund** is navigating a structural transition via a planned acquisition, with a special meeting to approve new trustees and an advisory agreement that maintains fee levels, suggesting a neutral, orderly transition. **FutureFuel Corp.** presents the most routine filing, with a standard director election and auditor ratification, lacking any financial performance data or material period-over-period trends. The overarching theme is one of risk asymmetry: one company is in a fight for survival, while others are engaged in normal governance housekeeping. No insider trading activity was reported in any of the filings, and no forward-looking guidance or capital allocation changes were disclosed, limiting the depth of trend analysis but sharpening the focus on the acute risk at Beauty Health.

4 high priority 4 total filings
· daily

US IPO Pipeline SEC S-1 Filings — August 12, 2026

The IPO pipeline for August 12, 2026, shows a mixed landscape dominated by pre-revenue biotech, cash-constrained fintech, and SPAC mergers with space-tech and data-analytics targets. Six filings were analyzed: two S-1s (Onconetix, BirchBioMed) and two S-1s with financial data (Fast Finance Pay Corp, SharonAI), plus two S-4 SPAC combinations (Space-Eyes, Mobilewalla). Period-over-period data reveals diverging financial health: Onconetix shows zero revenue momentum and a $135.4M accumulated deficit, while Fast Finance Pay Corp turned a $3.2M loss into $186K net income YoY but still burns cash. Space-Eyes and Mobilewalla represent high-risk/high-reward SPAC targets with $172.5M and $174.9M trust proceeds respectively, but face redemption risk. BirchBioMed's blank S-1 (no financials, no business description) signals a hollow or early-stage filing. The overarching theme is capital starvation in early-stage healthcare and fintech, contrasted by well-funded SPAC vehicles chasing space and data monetization.

6 high priority 6 total filings
· daily

US SEC Trading Suspension Halt Orders — August 12, 2026

Two Nasdaq-listed companies, CID Holdco, Inc. (Dot Ai) and Generation Income Properties, Inc., received Staff Determinations on August 6, 2026, to delist their securities due to non-compliance with listing standards, highlighting a severe liquidity and market confidence crisis in the micro-cap space. Both companies face imminent deadlines to appeal by August 13, 2026, but their financial fundamentals are deeply compromised, with no period-over-period revenue growth or positive operational metrics reported. CID Holdco failed to maintain a $50 million Market Value of Listed Securities (MVLS) despite regaining compliance on bid price, while Generation Income Properties failed the minimum bid price rule and a new deficiency in market value of publicly held shares. The absence of insider buying, positive forward guidance, or capital allocation actions (dividends/buybacks) in either filing underscores a complete lack of management conviction and financial flexibility. These delisting events signal a broader pattern of distress among micro-cap issuers with low market capitalizations and no path to organic compliance, creating high-risk situations for existing shareholders and potential forced selling. The compressed timeline for hearings and the lack of any positive catalysts make these filings actionable only for short sellers or those monitoring for complete equity wipeouts. No period-over-period comparisons, insider transactions, or forward-looking statements were available in the enriched data, limiting trend analysis but reinforcing the binary nature of the outcomes.

2 high priority 2 total filings
· daily

US Executive Officer Management Changes SEC — August 12, 2026

Today's digest covers 30 filings, with the first 23 newly published. The most material event is **BitGo Holdings**' CFO transition and simultaneous disclosure of a net loss, signaling governance stability but financial strain. **OptimizeRx** shows a concerning 30% YoY revenue decline, yet management reaffirms guidance, a mixed signal. **Arrive AI** faces a severe liquidity crunch triggered by a stock price floor provision, while **SPAR Group** reveals a bitter boardroom conflict with two directors removed for breach of agreement. **Home Depot**'s CEO medical leave is a high-profile but orderly succession event. Across the set, insider activity is minimal, but forward-looking data from OptimizeRx and Crown Crafts provides key calendar items. A pattern of weak shareholder support is evident at **PetMed Express**, where director elections saw significant opposition. The overall sentiment is neutral to negative, with governance and liquidity risks dominating.

30 high priority 30 total filings
· daily

US Corporate Board Director Changes SEC Filings — August 12, 2026

The 30 filings reveal a boardroom landscape dominated by routine governance transitions, with a few high-impact events creating actionable signals. The most critical development is the forced resignation of two directors at SPAR Group following a breach of agreements, signaling severe governance dysfunction. Conversely, strategic appointments at PubMatic, Madrigal Pharmaceuticals, and Citius Oncology suggest focused efforts to bolster commercial execution and R&D expertise. Financially, the data is mixed: OptimizeRx reported a 30% revenue decline but beat consensus, while Crown Crafts swung to profitability on tariff refunds. Insider activity is limited, but the CFO transition at BitGo and the CEO medical leave at Home Depot create near-term uncertainty. Key themes include a focus on independent board refreshment, a trend toward internal promotions for CFO roles, and notable shareholder dissent at PetMed Express. The overall risk profile is moderate, with opportunities in companies executing strategic hires against a backdrop of improving fundamentals.

30 high priority 30 total filings
· daily

US Merger & Acquisition SEC Filings — August 12, 2026

The August 12, 2026, M&A digest is dominated by a surge in SPAC activity, with five blank-check companies (BOA Acquisition Corp. II, OceanLight Acquisition Corp, TCGX Acquisition Corp, Inflection Point Acquisition Corp. V, and Embrace Change Acquisition Corp.) advancing their lifecycles through IPOs, regulatory approvals, or charter amendments to facilitate business combinations. The most material event is the completion of Modiv Industrial's merger into Global Net Lease, Inc., a high-certainty closure that removes a public entity. A notable operational outlier is Stem, Inc., which reported a mixed quarter with a 12% YoY revenue decline but a 63% surge in adjusted EBITDA and a 600 bps improvement in non-GAAP gross margins, alongside a strategic asset acquisition. The digest also includes two opaque filings (XMax Inc. and Pelican Acquisition II Corp) with no deal specifics, representing information gaps. The overarching theme is a busy SPAC pipeline with several companies nearing de-SPAC milestones, creating a binary event-driven catalyst calendar for the coming weeks.

12 high priority 12 total filings
· monthly

US Pre-Market SEC Filings Roundup — August 12, 2026

Overnight filings reveal a market bifurcated between aggressive growth investment and insider profit-taking. Key themes include a surge in director-level stock awards at Nu Holdings and STEM, signaling long-term alignment, contrasted with substantial insider selling at LandBridge Co LLC ($93.8M) and Charles Schwab ($5.01M). Earnings reports from Amcor and BETA Technologies show strong top-line growth driven by M&A and defense contracts, but with widening losses and cautious forward guidance, creating a mixed sentiment. Institutional filings from AI-Squared and Westpac highlight a continued focus on mega-cap tech and Chinese ADRs. The most actionable signals center on the transformative Berry acquisition at Amcor, the strategic investment in GCL Global's gaming subsidiary, and the complete exit of Goldman Sachs from Cantaloupe, which may indicate a loss of confidence in the stock.

34 high priority 16 medium 50 total filings
· daily

Biotech Small-Cap Approvals — August 11, 2026

The August 11, 2026 small-cap biotech digest captures four FALLBACK-type approvals, all classified as 'Other' and yielding neutral signals; there were zero NMEs, zero true biosimilars, and zero label expansions. The period highlights a quiet regulatory cadence from small-cap sponsors Baxter Healthcare Corp, Ascent Pharmaceuticals Inc, Umedica, and Fresenius Kabi USA, all for off-patent generics (levetiracetam, an unknown product, ranolazine, and nicardipine hydrochloride). No investment-grade upside or downside catalysts emerged: these approvals signal market standard generic entries without breakthrough, orphan, or accelerated designation perks. The highest-conviction neutral event is the entry of Fresenius Kabi's nicardipine hydrochloride—a hospital-based vasodilator—which underscores marginal pricing pressure in institutional generic markets but no material commercial shift. Key watch item: the lack of NMEs and biosimilars in this period highlights the absence of differentiated pipeline catalysts for the indicated small-cap sponsors.

4 total filings
· daily

New Drug Approvals (Original) — August 11, 2026

During the period of August 4-11, 2026, the FDA approved four biosimilar/generic drugs, all classified as FALLBACK approvals with neutral signals. No NMEs, biosimilars, or label expansions were approved, resulting in a low-catalyst week for investors. The approvals include LEVETIRACETAM (BAXTER HLTHCARE CORP), an unknown drug from ASCENT PHARMS INC, RANOLAZINE (UMEDICA), and NICARDIPINE HYDROCHLORIDE (FRESENIUS KABI USA), all targeting established markets with no disclosed peak sales or exclusivity data. The dominant theme is the continued commoditization of mature therapeutic areas, with no high-conviction signals for new commercial opportunities. Key risks include potential pricing erosion for originator drugs in these categories, but the lack of specific commercial details limits actionable insights.

4 total filings
· daily

Defense Manufacturing Contracts — August 11, 2026

The sole contract in this digest is a $139.8M firm-fixed-price award from NASA Goddard Space Flight Center to LANTERIS SPACE LLC for spacecraft bus manufacturing and on-orbit refueling services under the Restore-L mission, spanning 2016-2027. This is a civilian (NASA) contract with no defense component, reflecting continued investment in space servicing technology. The highest-conviction signal is the stable revenue base for LANTERIS SPACE, with $69M already outlayed, but the lack of public financial data limits tradable investment implications. Key risk includes execution risk on the fixed-price structure and potential policy sensitivity due to foreign ownership in a sensitive space program. Watch for NASA's Restore-L milestones and any follow-on contracts in space servicing.

1 total filings
· daily

VA Healthcare & Services Contracts — August 11, 2026

This digest covers a single $129.5 million civilian contract from the Department of Veterans Affairs awarded to Leidos Holdings, Inc. (via QTC Medical Services Inc) for medical disability examinations in the Pacific region. The contract is entirely non-defense, firm-fixed-price, and 85% complete ($110.7 million already outlaid), indicating strong near-term cash conversion but limited forward revenue visibility due to its one-year duration. The highest-conviction signal is the neutral rating, reflecting a fully executed contract with low execution risk but no catalyst for future growth. A key watch item is the potential re-competition for the Pacific region contract, which could threaten Leidos’s incumbent position.

1 total filings
· daily

New Federal Contractors — August 11, 2026

This digest covers two civilian agency contracts totaling $269.3 million, with zero defense-related awards, underscoring a non-defense procurement focus. The dominant theme is NASA's investment in space servicing infrastructure, led by LANTERIS SPACE LLC's $139.8 million fixed-price contract for the Restore-L mission, which signals strategic positioning in on-orbit refueling but carries execution risk due to its long duration and foreign ownership. The second award, a $129.5 million VA medical disability exam contract to Leidos Holdings (via QTC Medical Services), is nearly 85% complete, offering strong cash flow visibility but limited forward revenue. The highest-conviction signal is the NASA contract's technological moat in spacecraft bus manufacturing, though its private-entity status limits direct investment exposure. Key risks include potential policy changes affecting foreign-owned contractors in sensitive space programs and the VA contract's one-year performance period creating re-compete uncertainty.

2 total filings
· daily

Significant Contract Modifications ($10M+) — August 11, 2026

Over the period of August 11, 2026, two significant contract modifications totaling $269.3 million were awarded, both to civilian agencies (NASA and the Department of Veterans Affairs), with zero defense-related contracts. The dominant theme is stable, mandated civilian spending, with the VA contract for medical disability exams (Leidos Holdings) showing near-complete execution and strong cash conversion, while the NASA contract (Lanternis Space LLC) represents a long-duration, high-tech space servicing program with execution risk. The highest-conviction signal is the low-risk, high-cash-flow VA contract for Leidos, though it is a one-year award with limited forward visibility. A key risk is the long performance period and fixed-price nature of the NASA contract, which could pressure margins if technical challenges arise.

2 total filings
· daily

Contract Deobligations Alert — August 11, 2026

The two contracts analyzed total $269.3M in obligations, both from civilian agencies (NASA and VA), with zero defense-related awards. The dominant theme is stable, high-certainty cash flows from government services, with Leidos Holdings (via QTC Medical Services) showing an 85% outlay rate on a $129.5M VA contract, indicating near-complete execution and strong cash conversion. The highest-conviction signal is the Leidos contract's low execution risk, though its one-year duration limits forward revenue visibility. Key risk is the foreign-owned status of LANTERIS SPACE LLC on a sensitive NASA space servicing contract, which could face policy headwinds despite its technological positioning.

2 total filings
· daily

Contract Option Exercises — August 11, 2026

Across these two civilian agency contracts totaling $269.3 million, NASA's Restore-L mission contract with LANTERIS SPACE LLC ($139.8M) and the VA's medical disability exam delivery order with Leidos Holdings subsidiary QTC Medical Services ($129.5M) both signal stable, execution-phase revenue streams with low remaining risk. The 0/2 defense split highlights exclusive civilian sector exposure, with the VA contract nearing 85% completion and the LANTERIS contract having $69M already outlaid. The highest-conviction signal is the VA contract's high outlay rate, confirming near-complete cash conversion for Leidos. Key risks include LANTERIS's foreign ownership status in a sensitive space program and the VA contract's single-year performance period limiting forward visibility.

2 total filings